Multicentre survey to explore current survival of patients with acute myeloid leukaemia who failed induction chemotherapy

Abstract

Treatment options of PIF-AML still are limited and the prognosis, even recently, remains extremely poor. This survey shows that PIF-AML is still rarely cured without Allo-SCT and confirms the importance of initiating an urgent unrelated donor search in cases without a matched sibling donor. Moreover, the outcome of Allo-SCT is better in patients who achieve a good AML debulking before transplant. To reach this goal, new predictive scores and new protocols of salvage therapy (with target drugs or combinations) need to be explored urgently in PIF-AML.

Risk factors for induction failure of standard chemotherapy with anthracycline and cytarabine in Acute Myeloid Leukemia Patients

“…enasidenib and ivosidenib induction therapy with DA is still the backbone worldwide in the treatment for AML [15][16][17]. While a plethora of scientific publications for AML have substantiated an impact of older age, cytogenetics according to the ELN classification and allogeneic transplantation on the outcome of AML, only little information on risk factors for IF and its frequency after standard induction therapy with DA, is currently available [1,7,9,18]. Moreover, the frequency of the occurrence of IF in AML is often underestimated [3].…”

“…Generally, age over 60 years is considered to be a risk factor for IF and poorer outcome of AML [2]. Due to fact that the median age of onset of AML is over 70 years and significant improvements have been achieved in supportive care over the last decades, more and more elderly patients are treated in curative intention with intensive induction chemotherapy for AML and proceed to allogenic transplantation [7]. This could be a cause for an increased occurrence of IF after DA over the last years because advanced age is often accompanied by more adverse cytogenetics [3].…”